BofA/Merrill Lynch Downgrades Bio-Reference Laboratories (BRLI) Two-Notches to Underperform (Earlier)
Tweet Send to a Friend
BofA/Merrill Lynch downgraded Bio-Reference Laboratories (NASDAQ: BRLI) from Buy to Underperform with a price target of $32.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
